Journal of Pharmacovigilance

Max Feng

Publications

• Research Article
  Assessing Pancreatic Cancer Risk Associated with Dipeptidyl Peptidase 4 Inhibitors: Data Mining of FDA Adverse Event Reporting System (FAERS)
  Author(s): Xiaodong Feng, Amie Cai, Kevin Dong, Wendy Chaing, Max Feng, Nilesh S Bhutada, John Inciardi and Tibebe WoldemariamXiaodong Feng, Amie Cai, Kevin Dong, Wendy Chaing, Max Feng, Nilesh S Bhutada, John Inciardi and Tibebe Woldemariam
  
  Background: Identifying cancer risks associated with medicinal agents plays an important role in cancer control and prevention. Case reports of cancers associated with pharmacotherapy have been escalating in the Food and Drug Administration Adverse Event Reporting System (FAERS). The objective of this study is to assess the risk of pancreatic cancer associated with anti-diabetic drugs of dipeptidyl peptidase 4 (DPP 4) inhibitors with or without combination of metformin. Methods: Using the FAERS public database, the adverse event reports (ADRs) associated with widely used DPP 4 inhibitors with or without combination of metformin were generated and evaluated. Standardized pharmacovigilance tools were applied to detect the signal for cancer risks by calculating the proportional reporting ratio (PRR) and the reporting odds ratio.. View More»
  DOI: 10.4172/2329-6887.1000110

  Abstract PDF